Weekly Recap: Analysts cut ACAD targets and remlifanserin safety, efficacy

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) saw analysts trim price targets but mostly keep buy ratings as remlifanserin showed favorable safety and emerging 60 mg efficacy over six weeks; the company will continue two late—stage Alzheimer’s trials (dropping 30 mg), may tighten enrollment, and will r…